依赖USP14的IGF1R通过对BAP1进行上调来加剧高葡萄糖诱导的糖尿病视网膜病变
1Department of Ophthalmology, Jiangxia District, The First People's Hospital of , No.1 Zhifang Cultural Avenue, Jiangxia District, Wuhan City, 430200, Hubei Province, China.
Applied biochemistry and biotechnology
|March 31, 2025
概括
糖尿病视网膜病变 (DR) 的高葡萄糖水平通过USP14稳定增加胰岛素样生长因子1受体 (IGF1R). 抑制IGF1R或USP14可以防止DR相关的细胞损伤和铁亡.
科学领域:
- 眼科医生 眼科 眼科
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 糖尿病视网膜病变 (DR) 是糖尿病的一个严重的微血管并发症.
- 确切的分子机制背后的DR发病,特别是胰岛素类生长因子1受体 (IGF1R) 的作用,仍然不完全理解.
研究的目的:
- 阐明IGF1R及其调节通路在高葡萄糖诱导的视网膜细胞损伤中的作用.
- 调查在糖尿病视网膜病变的背景下,在IGF1R调节中,乌比奎丁特异性酶14 (USP14) 和BRCA1关联蛋白1 (BAP1) 的参与.
主要方法:
- 定量逆转录聚合酶连锁反应 (qRT-PCR) 和西式涂抹来评估基因和蛋白质表达.
- 测量了细胞活力,细胞亡,炎症标志物 (IL-1β,TNF-α),活性氧物种 (ROS),铁和谷氨水平.
- 共同免疫沉和局部化试验被用于确认蛋白质相互作用.
主要成果:
- 高葡萄糖增加了ARPE-19细胞中的IGF1R,USP14和BAP1蛋白水平.
- 抑制IGF1R降低了高葡萄糖诱导的亡,炎症和铁亡.
- USP14二维基提稳定了IGF1R;USP14沉默了受保护的细胞,而过度表达加剧了损伤.
- IGF1R与BAP1相互作用,IGF1R通过调节BAP1.1,使受保护细胞沉默.
结论:
- 在高葡萄糖诱导的糖尿病视网膜病变中,USP14介导的二维基化和IGF1R的稳定是至关重要的.
- 在DR中观察到的细胞损伤中,IGF1R和BAP1之间的相互作用起着重要作用.
- 针对USP14-IGF1R-BAP1轴为糖尿病视网膜病变提供了一个潜在的治疗策略.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
Cell Specific Gene Expression
13.3K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.3K
Insulin: The Receptor and Signaling Pathways
1.0K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.0K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Dipeptidyl Peptidase 4 Inhibitors
140
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
140


